Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | EIF4E | P06730 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767872 | 0.79 | NPC1 (0.41) | NPC1RAB9A | |
| SCHEMBL4255751 | 0.77 | ALOX15 (0.43) | NPC1RAB9AKMODPP4 | |
| SCHEMBL3263453 | 0.75 | KDM4E (0.37) | NPC1RAB9ABCHE | |
| SCHEMBL23638850 | 0.72 | S100A4 (0.46) | KMOGRM2EGLN2HSD11B1 | |
| SCHEMBL30598347 | 0.72 | S100A4 (0.46) | KMOGRM2EGLN2HSD11B1 | |
| SCHEMBL25205786 | 0.71 | NPC1 (0.46) | NPC1RAB9AKMOGRM2EGLN2 | |
| SCHEMBL9566507 | 0.71 | HTR2B (0.62) | NPC1RAB9AKMOGRM2DPP4 | |
| SCHEMBL15364221 | 0.71 | ALOX15 (0.43) | NPC1RAB9ABCHE | |
| SCHEMBL14488279 | 0.71 | AR (0.43) | AMY1ACYP1B1 | |
| SCHEMBL1219538 | 0.70 | NPC1 (0.53) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013004642-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | NPC1 389/4885RAB9A 2796/4885KMO 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.